Literature DB >> 11007515

Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity.

H Kobayashi1, N Sato, T Saga, Y Nakamoto, T Ishimori, S Toyama, K Togashi, J Konishi, M W Brechbiel.   

Abstract

For the purpose of radioimmunotherapy, labelling of monoclonal antibody with high specific activity is often necessary, especially when using a radionuclide with a shorter half-life. Polyamine dendrimers (PAMAM) are novel synthetic polymeric molecules with large numbers of amine residues on their spherical surface. In order to bind large numbers of radiometals to single antibody molecules, the generation-4 PAMAM (G4), which has 64 amines, was conjugated with 43 molecules of 2-(p-isothiocyanatobenzyl)-6-methyl-diethylene triamine penta-acetic acid (1B4M), a derivative of DTPA. This product [G4-(1B4M)43] was then conjugated with OST7, a murine monoclonal IgG1. We evaluated the achievable specific activity for 111In labeling, immunoreactivity, biodistribution, and tumor targeting in mice of the 111In- or 153Gd-OST7-G4-(1B4M)43 as compared with radiolabeled OST7-1B4M or 56C-1B4M. The maximum specific activity of 111In-OST7-G4-(1B4M)43 and 111In-OST7-1B4M was 470 and 8.7 GBq/mg (12,700 and 263 mCi/mg), respectively. Immunoreactivity of radiolabeled OST7-G4-(1B4M)43 and OST7-1B4M, as determined by the binding to KT005 cells expressing the antigen, was respectively 91% and 84% of that of 125I-labelled OST7. Biodistribution studies for preparations with maximum specific activity in normal mice 3 h after injection showed that 111In- or 153Gd-OST7-G4-(1B4M)43 cleared faster from the blood and accumulated more in the liver than did 111In- or 153Gd-OST7-1B4M. The dendrimer 1B4M [G4-(1B4M)64] itself showed similar saturation effects with metals. The radioactivity in all the other organs reflected the rapid clearance of radioactivity from the blood. 153Gd-OST7-G4-(1B4M)43 showed specific accumulation in the KT005 tumor. In conclusion, we could successfully bind 49 times as many metal atoms to an antibody molecule as is possible with conventional metal labeling for indium and gadolinium, and did so with minimal loss of immunoreactivity. When we achieved radiolabeling with maximum specific activity, Gd conjugate showed better biodistribution than In conjugate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007515     DOI: 10.1007/s002590000293

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  18 in total

1.  Strategies for the preparation of bifunctional gadolinium(III) chelators.

Authors:  Luca Frullano; Peter Caravan
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

Review 2.  Imaging and drug delivery using theranostic nanoparticles.

Authors:  Siti M Janib; Ara S Moses; J Andrew MacKay
Journal:  Adv Drug Deliv Rev       Date:  2010-08-13       Impact factor: 15.470

Review 3.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

Review 4.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

5.  Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography.

Authors:  Kido Nwe; Diane E Milenic; Geoffrey L Ray; Young-Seung Kim; Martin W Brechbiel
Journal:  Mol Pharm       Date:  2011-09-21       Impact factor: 4.939

Review 6.  Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.

Authors:  Sue Hyun Lee; Jung Bok Lee; Min Soo Bae; Daniel A Balikov; Amy Hwang; Timothy C Boire; Il Keun Kwon; Hak-Joon Sung; Jae Won Yang
Journal:  Adv Healthc Mater       Date:  2015-06-29       Impact factor: 9.933

Review 7.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

Review 8.  Macromolecular and dendrimer-based magnetic resonance contrast agents.

Authors:  Ambika Bumb; Martin W Brechbiel; Peter Choyke
Journal:  Acta Radiol       Date:  2010-09       Impact factor: 1.990

9.  Asymmetric peptide dendrimers are effective linkers for antibody-mediated delivery of diverse payloads to b cells in vitro and in vivo.

Authors:  Neha D Shah; Harendra S Parekh; Raymond J Steptoe
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

10.  Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.

Authors:  Conrad Chan; Zhongli Cai; Raymond M Reilly
Journal:  Pharm Res       Date:  2013-04-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.